“We are excited to welcome Dr. Becich to our SAB,” commented Anthony Johnson, President/CEO of Empire Genomics. “He has tremendous knowledge in cancer biology and informatics, which are critical aspects of our objectives in personalized medicine."
Buffalo, New York (PRWEB) July 24, 2012
Empire Genomics, a leader in the field of genomic molecular diagnostics and personalized medicine, is pleased to announce the appointment of Michael J. Becich, M.D., Ph.D., to its Scientific Advisory Board. Dr. Becich is a leading expert on cancer biology and biomedical informatics.
“We are excited to welcome Dr. Becich to our SAB,” commented Anthony Johnson, President/CEO of Empire Genomics. “He has tremendous knowledge in cancer biology and informatics, both of which are critical aspects of our corporate objectives in personalized medicine. We look forward to working with Dr. Becich to continually innovate and translate cutting edge research into clinical molecular testing solutions.”
Dr. Michael J. Becich is a Professor and the founding chair of the Department of Biomedical Informatics at the University of Pittsburgh School of Medicine. He is jointly appointed as Professor of Pathology as well as Information Sciences/ Telecommunications and Clinical/Translational Sciences. He is the Co-director of the University of Pittsburgh Clinical and Translational Science Institute and Associate Director of the University of Pittsburgh Cancer Institute. His current research focuses on developing tools to couple human biorepositories and clinical phenotypes derived from electronic medical records to expression data derived from high throughput genomics and proteomics.
“We have entered the era of personalized medicine in which the combination of diagnostics in molecular pathology and analytics fueled by informatics will significantly advance the efficient customization of treatment. Empire Genomic’s vision and leadership team are well positioned to accelerate the path to personalized medicine through its diagnostic applications which will aid both in the development and validation of biomarkers critical to drug discovery and precision medicine,” said Dr. Becich.